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OBJECTIVES: To describe health care resource consumption
and subsequent costs in GERD management in primary care
centers in Spain. METHODS: In this retrospective, observa-
tional study, a random sample of all patients who visited a
primary health care center in Spain for a reason related to GERD
over a 4 months period were included. Patients with GERD
symptoms were invited to participate, and those who accepted
completed an interview visit during which clinical data were
collected. Information regarding health care resources (diagnos-
tic methods, physicians visits and hospitalization days) during
the time between the two visits was collected, transformed into
annual consumption, and expressed as 2008 € (according to
public tariffs available and rate of inﬂation). RESULTS: Overall,
63,416 patients were identiﬁed during the study period. In 1727
(2.7%) patients GERD was a reason for the visit. Of these, 579
patients were randomly selected and 87% participated in the
study; Mean age was 60 years (SD: 15,7), 59% were women.
Patients with a high symptom load (frequency: 32 days or daily;
and intensity: moderate or severe), made a mean number of
visits per year to a PCP of 5.35 compared with 2.2 visits in
patients with a low symptom load; visits to a gastroenterologist
were 1.55 vs. 0.45 and to other specialists were 0.64 vs. 0.17,
with hospitalization days 0.61 vs. 0, respectively. Total direct
medical costs increased on average from €186€ to €578€ to €956
when patient-reported heartburn intensity varied from mild to
moderate to severe, respectively; and from €314 to 623€ to
€1076 when acid regurgitation was also considered. CONCLU-
SIONS: Higher symptom load at baseline leads to an increasing
use of health care resource. Further research is needed to better
understand the causes as well as identifying potential GERD
management approaches that could better optimize health care
resource utilization.
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OBJECTIVES: To compare real-world vs. labeled anti-tumor
necrosis factor dosing in adults with CD. METHODS: A ret-
rospective claims analysis was conducted for CD patients aged
18 years using Wolters Kluwer Health’s Source Lx Longitu-
dinal patient database. Newly initiated adalimumab (ADA) or
inﬂiximab (IFX) patients, determined by a 90-day absence of
claims for either agent prior to the index date, with continuous
enrollment and therapeutic persistence for the study duration,
were analyzed. Labeled dose was calculated monthly as the
cumulative sum of 40 mg syringes (ADA) or 100 mg vials (IFX)
required from the ﬁrst day of the index month through Decem-
ber 31, 2007, inclusive of induction and maintenance dosing.
The IFX labeled dose assumed 4–8 vials per infusion, repre-
senting the labeled dose range (5 mg/kg–10 mg/kg) for an
average patient weighing 71 kg, which was the mean weight of
patients in the IFX clinical trial. Mean cumulative utilization
was analyzed for each drug monthly and compared with the
labeled dose. RESULTS: There were 1299 patients with ADA
(average age 41.6; 61% female) and 2118 patients with IFX
(average age 42.9; 57% female). For ADA, 48.6% patients
were at or below the labeled dose, while 51.4% were above the
labeled dose. The average difference between mean prescribed
dose and labeled dose for ADA was +5.51 syringes. For IFX,
57.7% patients were below the lowest labeled dose of 5 mg/kg,
32.9% were within the 5 mg/kg to 10 mg/kg range, while only
9.4% were above the highest labeled dose of 10 mg/kg. The
average difference between mean prescribed dose and lowest
labeled dose (5 mg/kg) was -2.10 vials. CONCLUSIONS: In
CD, most (51.4%) ADA patients were above the labeled dose,
while few (9.4%) IFX patients were above the labeled dose.
Payers should analyze their own data to determine if these
same trends are seen and, determine the impact of these dosing
patterns to the plan.
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OBJECTIVES: To assess the direct hospital cost of Crohn’s
Disease (CD) in daily clinical practice in Spain. METHODS:
Descriptive, naturalistic, retrospective, multicenter study of
moderate/severe CD patients. Pooled data from ten hospitals,
each including ten outpatients, were analysed. Clinical records
were reviewed for patient demographics, disease characteristics
and use of resources. A Markov model analysis was used to
estimate the total cost per patient by disease severity state. The
study evaluated direct medical costs in 2007 from a Spanish NHS
perspective. The time horizon was a 3-year period. A sensitivity
analysis was performed to assess the impact of variables on the
direct medical costs of CD. RESULTS: A total of 178 patients
(median age 37 (11) years; median time since diagnosis 9 (5)
years) were included. Disease location was ileocecal in 47.7%,
ileal in 32% and colonic in 19.7%. The most frequent symptom
pattern was inﬂammatory (51.1%) and 39.3% presented peria-
nal disease. The total annual cost per patient was €7722.66.
Hospital admissions accounted for 57% of the total costs. The
costs associated with drug treatment were 33% which are
divided in 27% for biological therapies and 6% for conventional
therapies. Other costs including visits, tests and surgical inter-
ventions accounted for 10%. The course of the disease showed a
decline in remission/mild states and an increase in severe states
being the average cost per patient and cycle of €228.578 and
€2481.18 respectively. The probability of receiving a biological
therapy was the only variable with a signiﬁcant impact in the
total cost of CD management. CONCLUSIONS: The direct cost
of CD management is due mostly to hospital admissions and to
the intense use of resources in the most severe disease status. The
introduction of new therapies that allow a signiﬁcant improve-
ment in the evolution of patients’ disease could provide relevant
economic savings for the Spanish NHS.
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